CN114717318A - CeRNA (ribonucleic acid) regulation and control network for early diagnosis or detection of cerebral aneurysm and application thereof - Google Patents

CeRNA (ribonucleic acid) regulation and control network for early diagnosis or detection of cerebral aneurysm and application thereof Download PDF

Info

Publication number
CN114717318A
CN114717318A CN202210407039.XA CN202210407039A CN114717318A CN 114717318 A CN114717318 A CN 114717318A CN 202210407039 A CN202210407039 A CN 202210407039A CN 114717318 A CN114717318 A CN 114717318A
Authority
CN
China
Prior art keywords
cerebral aneurysm
gene
detection
miat
galnt10
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210407039.XA
Other languages
Chinese (zh)
Other versions
CN114717318B (en
Inventor
黄毅
于茜
高彤
孙杰
高翔
聂晟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo First Hospital
Original Assignee
Ningbo First Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo First Hospital filed Critical Ningbo First Hospital
Priority to CN202210407039.XA priority Critical patent/CN114717318B/en
Publication of CN114717318A publication Critical patent/CN114717318A/en
Application granted granted Critical
Publication of CN114717318B publication Critical patent/CN114717318B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a ceRNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof, which is characterized in that the ceRNA regulation network is an lncRNA MIAT-miRNA-17-3p-GALNT10 regulation network, wherein lncRNA MIAT gene is shown as SEQ ID No.1, miRNA-17-3p gene is shown as SEQ ID No.2, GALNT10 gene is shown as SEQ ID No.3, the application of the ceRNA regulation network in preparation of medicines and kits for early diagnosis or detection of cerebral aneurysm is realized, the molecular marker miRNA-17-3p is low expressed and the MIAT and GALNT10 genes are high expressed in early diagnosis or detection of cerebral aneurysm; the method has the advantages of conveniently and quickly detecting the cerebral aneurysm on a molecular level, high detection efficiency, strong specificity and high sensitivity.

Description

CeRNA (cellular ribonucleic acid) regulation and control network for early diagnosis or detection of cerebral aneurysm and application thereof
Technical Field
The invention relates to the technical field of auxiliary diagnosis of cerebral aneurysm, in particular to a ceRNA (ribonucleic acid) regulation and control network for early diagnosis of cerebral aneurysm and application thereof.
Background
Cerebral aneurysm (IA) is a common cerebrovascular disease with high disability rate and mortality. The breakage of IA is the main cause of death, the fatality rate reaches 35%, the disability rate is about 30%, and only less than 30% of IA breakage patients can recover independent life. The traditional diagnosis of cerebral aneurysm is based on imaging means for examination, and patients often go to a hospital for diagnosis after the occurrence of relevant symptoms. IA is usually asymptomatic before rupture and is limited by the imaging diagnostic techniques and costs, patients are consciously at risk for debilitating, and 80% -90% of unbroken aneurysms are occasionally found. The IA is also called a 'timing bomb' of the brain, which is very easy to break suddenly when the blood pressure rises due to accidental tension, force, fatigue and the like, and once the IA breaks, the IA can endanger the life or leave serious sequelae, thus bringing great threat to the life of people. The cerebral aneurysm has no sign before rupture, the death rate is extremely high, and approximately 1/3 patients with the cerebral aneurysm die after the disease is sent to a hospital for treatment. Therefore, the development of molecular markers for early prediction of cerebral aneurysm is of great significance in prevention and treatment of the disease.
With the maturation of transcriptome sequencing and microarray technology, a number of RNAs were identified and demonstrated to have important roles in IA. In recent years, researchers have found that competing endogenous rnas (cernas) have a unique effect on disease. The cerRNA hypothesis is mainly that long non-coding RNAs (lncRNAs) act as molecular sponges to attract micro RNAs (miRNAs), and indirectly regulate messenger RNAs (mRNAs) by competing for binding to shared miRNAs, and miRNAs play a role in connection in cerRNA and are important gene transcription regulators. For example, the long-chain non-coding RNA MALAT1 indirectly regulates the expression of miRNA-143 target gene VEGFA by competitive combination with miRNA-143, thereby influencing the damage process of vascular endothelial cells. The expression of ectodermal nerve cortex 1 can be regulated by a myelocytoma oncogene to influence the apoptosis process of vascular endothelial cells and the like. MIAT can also promote the expression of high mobility group protein (HMGB1) through the sponge miR-204-5p, thereby regulating the damage of brain microvascular endothelial cells after cerebral ischemia. At present, there are few research reports about the analysis of the cerRNA network and the correlation of cerebral aneurysm at home and abroad.
Disclosure of Invention
The invention aims to solve the technical problem of providing a cefRNA regulation and control network with strong specificity and high sensitivity for early diagnosis or detection of cerebral aneurysm and application thereof, wherein the expression level of miRNA-17-3p is in negative correlation with the disease of the cerebral aneurysm, and the expression level of MIAT and GALNT10 genes is in positive correlation with the disease risk of the cerebral aneurysm.
The technical scheme adopted by the invention for solving the technical problems is as follows: a cerRNA regulation network for early diagnosis or detection of cerebral aneurysm is a IncRNA MIAT-miRNA-17-3p-GALNT10 regulation network, wherein the nucleotide sequence of IncRNA MIAT is shown as SEQ ID No.1, the nucleotide sequence of miRNA-17-3p is shown as SEQ ID No.2, and the nucleotide sequence of GALNT10 is shown as SEQ ID No. 3.
The application of the ceRNA regulation and control network for early diagnosis or detection of cerebral aneurysm in preparation of drugs for early diagnosis or detection of cerebral aneurysm is provided.
The medicine promotes the expression of lncRNA MIAT gene and/or promotes the expression of GALNT10 gene and/or inhibits the expression of miRNA-17-3p gene in early diagnosis or detection of cerebral aneurysm.
The application of the ceRNA regulation and control network for early diagnosis or detection of the cerebral aneurysm in preparation of a cerebral aneurysm early diagnosis or detection kit.
The kit comprises a MIAT gene fluorescent quantitative PCR specific upstream primer: 5'-CAAGGTCCACAGAACGAG-3', MIAT Gene fluorescent quantitative PCR specific downstream primer: 5'-TAGCCCTAACGCCAAAT-3', respectively; GALNT10 gene fluorescent quantitative PCR specific upstream primer: 5'-AAAGTTGGTGGTGTTGGGAAAG-3', GALNT10 Gene fluorescent quantitative PCR specific downstream primer: 5'-AGTGGGTGGCAGGTTGGTT-3' is added.
The miRNA-17-3p gene expression level is in negative correlation with the cerebral aneurysm disease, and the MIAT gene and the GALNT10 gene expression level are in positive correlation with the cerebral aneurysm disease risk.
Compared with the prior art, the invention has the advantages that: the invention discloses a ceRNA regulation and control network for early diagnosis or detection of cerebral aneurysm and application thereof for the first time, wherein the regulation and control network comprises a long non-coding RNA MIAT, a micro RNA miRNA-17-3p and a messenger RNA gene GALNT10, the lncRNA MIAT and GALNT10 genes are highly expressed in cerebral vascular tissues and plasma of the cerebral aneurysm, and the miRNA-17-3p is lowly expressed in cerebral vessels and plasma of patients with the cerebral aneurysm. The mechanism of the method is that LncRNA MIAT sponges miR-17-3p can regulate the expression of a target gene GALNT10 to participate in the pathological development process of the cerebral aneurysm. The LncRNA MIAT-miR-17-3p-GALNT10 cerRNA network axis regulates the infiltration capacity of macrophages through an NF-kB signal channel and participates in the development process of IA. Therefore, the detection kit based on the detection of the ceRNA network combined marker MIAT/miR-17-3p/GALNT10 gene/protein expression level can conveniently and quickly realize the detection of the cerebral aneurysm on a molecular level, has high detection efficiency and strong pertinence, and simultaneously, the ceRNA network combined marker target MIAT/miR-17-3p/GALNT10 is used as an innovative application of auxiliary diagnosis, detection and screening of the cerebral aneurysm.
In conclusion, the detection kit based on the detection of the expression level of the ceRNA network combination marker MIAT/miR-17-3p/GALNT10 can conveniently and quickly realize the detection of the cerebral aneurysm on a molecular level, wherein the molecular marker miRNA-17-3p is low in expression, and the genes of the MIAT and GALNT10 have the risk of suffering from the cerebral aneurysm when being high in expression, have high detection efficiency and strong pertinence, and are beneficial to early discovery and timely treatment of the cerebral aneurysm.
Drawings
FIG. 1 is a flow chart of screening differential genes in bioinformatics;
FIG. 2 is a graph of the differential analysis of 3 RNAs in multiple cerebral aneurysm gene expression GEO databases;
FIG. 3 is a weighted gene co-expression network analysis (WGCNA) of miRNA and mRNA of the GEO database
FIG. 4 is a diagram of a cenRNA network mulberry base for constructing lncRNA-miRNA-mRNA in a GEO database of cerebral aneurysm;
FIG. 5 shows that differential genes were screened and clinically verified to result in significant differences between case and control groups (p <0.05, p < 0.01) for the combined marker of CERNA, MIAT/miRNA-17-3p/GALNT 10;
figure 6 is a ROC curve analysis of the expression of the cerana combination markers in plasma of cerebral aneurysm patients.
Detailed Description
The invention is described in further detail below with reference to the accompanying examples.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
1. GEO data collection for cerebral aneurysm patients
The entire analysis work is shown in fig. 1. The GEO database (http:// www.ncbi.nlm.nih.gov/GEO) is called GENE EXPRESSION OMNIBUS, is a GENE EXPRESSION database created and maintained by the national center for Biotechnology information NCBI, and mRNA/lncRNA/miRNA chip datasets related to cerebral aneurysms are all from the GEO database. The keywords of "cerebral analysis/bridge analysis/intracrarial analysis" and "Homo sapiens" and "Expression profiling by array" and "Non-coding RNA profiling by array" are used for co-searching 20 pieces of information. And (3) filtering standard: 1) the sample type is related tissue of cerebral artery; 2) need to include a healthy group; 3) the detection method is a microarray chip, and based on the conditions, 6 sets of chip data (mRNA and lncRNA share 5 sets of chip data, and miRNA has 1 set of chip data) are included in the research. Finally, 68 samples were used for mRNA/lncRNA analysis and 17 samples were used for miRNA analysis.
2. Visualization of RNA differential expression analysis chromosomal location
Limma (v 3.48.3) package was used to screen for differentially expressed RNA. I log2 FC | > 1, p.adj <0.05 is mRNA/ncRNA screening standard. And the lower limit of log2 FC | > 1, p <0.05 is miRNA screening standard. Differential gene expression and chromosomal location were visualized using the ggplot2 (v3.3.5) package and the OmicCircos (v1.30.0) package. The differential genes are labeled as denmrna, DElncRNA, and denmirna, respectively (fig. 2).
3. Weighted gene co-expression network (WGCNA) analysis of DemiRNA and DEmRNA
Based on the previously identified DemiRNA and DEmRNA, weight gene co-expression network analysis (Weighted gene co-expression network analysis, WGCNA, v1.70.3) was performed to obtain candidate module genes related to IA. WGCNA is an analysis method for identifying a gene coexpression network based on topology overlap, finding out a gene module which is expressed cooperatively and correlating with a phenotype. Performing calculation processing through a WGCNA packet, selecting a soft threshold power (beta) to enable the correlation of nodes in the co-expression network to reach 0.9, converting a correlation matrix into an adjacent matrix, converting the adjacent matrix into a Topological Overlapping Matrix (TOM) so as to obtain different modules, associating the divided modules with phenotypes, and selecting the modules with high correlation degree with the IA diseases for subsequent analysis. Genes selected after WGCNA analysis were labeled WGCNAmRNA and WGCNAmiRNA, respectively (fig. 3).
4. Construction of a cenRNA regulatory network lncRNA-miRNA-mRNA
Performing the ceRNA network prediction on the selected WGCNAmRNA, WGCNAmiRNA and DelncRNA: the MultiMIR (v1.14.0) package centralizes 8 websites predicting miRNA target genes, DIANA-microT-CDS, ElMMo, MicroCosm, miRanda, mirDB, PicTar, PITA and TargetScan, respectively. Setting the threshold at 20%, predicting the mRNA target gene of WGCNAmiRNA and intersecting with WGCNAmRNA, using LncBook (https:// ngdc.cncb.ac.cn/LncBook/index) database to predict the lncRNA target gene of WGCNAmiRNA and intersecting with DElncRNA, labeled as MultiMiRmiRNA-MultiMiRmRNA and lncBookmiRNA-lncBooklncRNA, respectively. Based on the assumption principle of the ceRNA that lncRNA has expression correlation with mRNA, performing correlation analysis on WGCNAmRNA and DelncRNA, taking | R | >0.6 and P <0.01 as a screening standard, respectively labeling CORmRNA and CORlncRNA, taking intersection with a previous relation net, and respectively labeling COR1miRNA-COR1mRNA and COR2miRNA-COR1 lncRNA. And (3) constructing a ceRNA network of lncRNA-miRNA-mRNA by taking common miRNA of COR1miRNA and COR2 miRNA. Gene expression relevance, the cerRNA network, were data visualized using the ggplot2 (v3.3.5) package, VennDiagram (v1.7.0) package, ggalluvial (v0.12.3) package, and Cytoscape (v3.7.2) software, respectively.
5. Collecting clinical samples
The clinical samples verify the marker combination of the differential expression of the blood plasma of patients with cerebral aneurysm and the blood plasma of healthy control group patients, and evaluate the marker combination as a candidate marker for predicting the cerebral aneurysm, so as to be used for the possibility of early auxiliary diagnosis or efficacy monitoring of the cerebral aneurysm. The method comprises the following specific steps: patient plasma samples were collected for validation experiments under a precursor agreement with hospital ethics committee and informed consent of the patients. The collected samples included 10 (5 males, 5 females, age: 63.40. + -. 7.15) in the control group and 20 (12 males, 15 females, age: 64.04. + -. 6.94) in the experimental group.
6. Fluorescent quantitative RT-qPCR (reverse transcription-quantitative polymerase chain reaction) verification of CERNA (cellular ribonucleic acid) network marker
Plasma RNA is extracted by adopting a conventional phenol chloroform method, and the change of expression levels of selected MIAT, LINC01094, miRNA-17-3p, GALNT1, GALNT5, GALNT10, GPX8 and WNT5A in the ceRNA network marker combination is verified by adopting fluorescent quantitative RT-qPCR. Primer design is carried out on genes MIAT, LINC01094, GALNT1, GALNT5, GALNT10, GPX8, WNT5A and beta-actin by using Primer 5.5 software, wherein the gene sequence position of the MIAT is hg38, Chr22: 26,646,452 and 26,669 and 655; the GALNT10 gene sequence positions hg38, Chr5: 154,190,733-154,420, 984; the gene sequence of miRNA-17-3p is hsa-miR-17-3p, MIMAT0000071, 5'-ACUGCAGUGAAGGCACUUGUAG-3'; MIAT gene fluorescent quantitative PCR specific upstream primer: 5'-CAAGGTCCACAGAACGAG-3', MIAT Gene fluorescent quantitative PCR specific downstream primer: 5'-TAGCCCTAACGCCAAAT-3', respectively; GALNT10 gene fluorescent quantitative PCR specific upstream primer: 5'-AAAGTTGGTGGTGTTGGGAAAG-3', GALNT10 Gene fluorescent quantitative PCR specific downstream primer: 5'-AGTGGGTGGCAGGTTGGTT-3', respectively; RT-qPCR primers for hsa-miRNA-17-3p (CD 201-0017) and internal reference U6 (CD 201-0145) were from Peking Tiangen. Total RNA concentration and mass were determined using a Nano Drop ultramicro spectrophotometer. cDNA Synthesis was performed using the reverse transcription Kit reverse air First Strand cDNA Synthesis Kit (Thermo Fisher SCIENTIFIC, USA). The qRT-PCR amplification of cDNA was performed using SYBR Green PCR Master Mix (Roche, US) on a LightCycler480 fluorescent quantitative RT-qPCR system. Amplification conditions: firstly, denaturation at 95 ℃ for 10 min; then annealing reaction is carried out for 40 cycles at 95 ℃ for 30s, 56 ℃ for 30s and 72 ℃ for 1 min; then extension reaction was carried out at 72 ℃ for 5 min.
7. Statistical treatment
Expression data were processed using the 2- Δ Δ Cq method, visualized using GraphPad Prism 8 and statistically compared. P <0.05, is considered statistically significant.
8. Results of the study
Through WGCNA analysis, a cerRNA regulation and control network is preliminarily constructed, and 562 regulation and control relations are obtained by taking a common miRNA part of COR1miRNA-COR1mRNA and COR2miRNA-COR1lncRNA, wherein the regulation and control relations comprise 3 lncRNA nodes, 82 miRNA nodes and 42 mRNA nodes. Combining the above study results, a sanger-based map of the ceRNA network was drawn (fig. 4).
The analysis of the ceraRNA channel finds that the screened gene combination markers are mainly focused on glycosylation related channels (mucin type O-glycan biosynthesis and other types of O-glycan biosynthesis related channels). As shown in fig. 5A, the core regulatory axis is: MIAT/LINC01094 ↓ -miRNA-17-3P ↓ -GALNT1/GALNT5/GALNT10/GPX8/WNT5A ×).
Aiming at the screened core regulation and control axis, the result is further verified and analyzed by collecting clinical case plasma samples and developing an RT-qPCR experiment. As a result, the expression levels of lncRNA MIAT (p <0.01, FIG. 5B) and GALNT10 (p <0.05, FIG. 5C) genes were found to be significantly higher in the plasma of cerebral aneurysm patients than in the control group, while the expression level of miRNA-17-3p was significantly down-regulated (p <0.05, FIG. 5D) in the plasma of cerebral aneurysm patients. However, there was no significant difference in the expression levels of LINC01094, GALNT1, GALNT5, GPX8 and WNT5A genes among the case-control groups (p > 0.05, FIG. 5E-I).
Further, we analyzed the diagnostic ability of the combination of the ceRNA network markers using ROC curve analysis. Results displayMIATThe offline AUC area of the gene expression level was 0.83, the sensitivity at the optimal critical point was 77.8%, the specificity was 80.0%, the AUC area of the GALNT10 gene expression level was 0.79, the sensitivity at the optimal critical point was 74.1%, the specificity was 90.0%, the AUC area of the miRNA-17-3p expression level was 0.72, the sensitivity at the optimal critical point was 66.7%, the specificity was 90.0%The sex is 30.0%; analysis after two-two combination showed that AUC area after combination of MIAT and GALNT10 expression levels was 0.87, sensitivity at the optimal critical point was 70.4%, specificity was 90.0%; the AUC area of the combination of the expression levels of the MIAT and the miRNA-17-3p is 0.92, the sensitivity at the optimal critical point is 100.0 percent, and the specificity is 80.0 percent; the AUC area after the combination of GALNT10 and miRNA-17-3p expression levels was 0.88, the sensitivity at the optimal cut-off point was 92.6%, and the specificity was 70.0%; the AUC area after the combination of the three markers was 0.96, the sensitivity at the optimal cut-off point was 92.6%, and the specificity was 90.0%.
The kit for detecting the expression quantity of the ceRNA network combination marker and the application thereof have the advantages of accuracy, reliability, flexibility, rapidness, economy and economy in the detection kit for the auxiliary diagnosis of the cerebral aneurysm. The kit is adopted to detect the expression levels of the CERNA network combined markers MIAT and GALNT10 genes, and can quickly and reliably provide reference for auxiliary diagnosis, detection or drug screening of the cerebral aneurysm.
While the preferred embodiments of the present invention have been illustrated, various changes or modifications can be made by one skilled in the art without departing from the scope of the present invention.
The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Those skilled in the art should also realize that changes, modifications, additions and substitutions can be made without departing from the true spirit and scope of the invention.
Sequence listing
<110> Ningbo City first Hospital
<120> a ceRNA regulatory network for early diagnosis or detection of cerebral aneurysm and application <160> 3 thereof
<170> PatentIn version 3.1
<210> 1
<211> 10194
<212> DNA
<213> Artificial sequence
<223> lncRNA MIAT gene (CAGCTACAAAGACGACGCCGGCTGCGCTCGCGGGACCAGAGGGAGGGAGGCTGCGGACGAGTGCGGGGAGGAGTTTGAGATGGGAGGCGCTTGCAGGGGCTCCCCCAGTTCTGCGCTGTGAGCCGGGGCACAAAGAGCCCTCTGCACTAGCGCCGCAGGACCGCGGACCCGAGTTGGAGGCATCTGTCCACCCATGTGGTTCCAGACACGTTCATGTGGCCACCATGACCCCGTCGGCATCACAGGGGTAACCAAGGTCCACAGAACGAGGGGAAAGGGTCACTGTGGATCAAGCCAGGCTCCTCTGAGCAGTCCAGGGTCTATTTACAGAGAGCAGCAAGTTCCTGGGACAGAGGAGACAGAAGGGAATTTCCAGGTTCTTCAGGACGTTCACAACCACACTGAGAAGCATCTTTGCAGATAAGTATTTAAACTTACCAGCCCATAGCCTACCAGCCTGCCCTCTTCTGGTCTGTGCAGGAAAGTGTAGTATCCTAGAATGCCAAAGTGGGAGGGGAAATGGGTGATGTAGCTCATTCTCTTTTCTACCTCTATGGAAGAAAGAAAGAGCCTGTCCCCATTTTGTGGGGTCCCAGAAAGGGTGATTTTCACACTTCACATTTGGCGTTAGGGCTAGTATTTCACAAACATTACCGTCTGGAACTTTTGAAGGCTGAGTTAAATGACTTCATCTTGTGTACTTGTAGAACTGCTATTAGAAGGAGGCTGGGGACTCCCTGATGATGTGAACCAGCCCTTCTCTTCTCAGTTTCAGCACTTTGTGATCATATTTATAAACCTTGGACAGGGCTCCTTGGCCTTAGAGTTAAGTGAAGAGTTAACACTGTGACTTTAGATGCATTTTTCTCAGTGTAAGTGTCTGAGCTCATCTCCAGTTCTGGACTCGTGCCCCCACTCCCGGGTGCTGACAGCAAGCTCTGAAGATATGCTGAGAGAGCTCCCTGACTCTCCTGACTCAGGTCTGCCAGTTGATGAAGACAGCACAGTTGTTACCAAAAACAAAACCTGGCAGATGGTCCTAGGTCAGGATTAGTGGTCATTCTCTGGTCTTCTCCAGACTGGTGACACAGGGTGGTCTTAAAAGAGTCCTAGTCCAGCCTCTGGCTCCCCGAATTTCCTCTGGTGCATGGGGCATCAGGAAAGGGCAGGGGAGAAGGAGGGGGAGCAGAAAAATAACTGAGGCTGGGCAGAAGGGTCCCTTCCATTTCCCATCCATTGCTTCAAACAATGGGTGATTACCGTGCACCTTGAGTGAATGTCAAGGCAGGAAGGGTTCCAGGGCCACCCAGTGTGGCAGGAGCAGAGCTGGGATCAGAATTCTGGATTCCTGACTCTCCGTTCAGCTGCTATTCAGCTATCACCAAGCTGCTGAGTTTGTCCTACTTTCTCCTGGGTCACATTCTGCTGTTGTTGGGAAACAGGGAGTGAGTGAAGGGAACCTGGGAACCCTTCTCCCCTCACCTTTTAAGGATGTTCTGGGGTGGAATAAAGAGAGGTGGAGGGTGGGGTGCCTGGGCCCAGCCTCCCTGGCTCCTGGTCCTTCTTTCTTCAGCAGGGAGTTCTGGCAAGGCCTGGGCCTGGGGAGGGGGCCTGGGTGCAGTTTTCTCCTGCGGTGTGGTTGGCTCTTTTGTCTTCCAGGATGGGCCTGTGGGGTCTGTGTGGGGAAGGAAGGAGCTGGGAGCCTGGGCTGCCTGTGTGTCGGCTGGATGCTGCCAGCACCGGCATGGACCAAGCAACTTCTCTGAGCCAGATGCTGGGGACGCAGAGGTGAACCCAGAGACATGATCCCATCTGCTCAGATCTTCATGTCAGAACACGCTTTATTACAGTCTCGGCAAGGGGGTGGCTCCATCTGGGCCGCATCTCCAGGACTCCTGGCCTGGACTTCTCTTTGGACCTCGGGTGACCTTGGATTCTGGCCACAGTGACTTAGCGGTCAGACTCCGGTGGTTTTCTAGCCCGCTGGGTGACTCCCTGAAGATCTCATCCTCTTCACACCTGTTGGGATGGAGCCTCCCATGGATAGGAACTCTTCCTGGTTGATGCTCAGCAGATGACTGATCTGGCTCTGGAGGACAGCTCCAGGGGTATGAGGGAGGCCTGGCAGCCCACTACTCCCTCCTCACCTGCTCGGGCCCTGCCTGCTGGGCCCTATTGTCTGGGTCTGGGGGCCCTTTCCTGCCCCATGTGAACTTGATTCCTCCTCGCGTTTCTGCCGGTGACCAGACAGAGCCTGGCCTGGGCCAAGTCCCCACTGACCACACTTTCCCCAAGGCTGGGTCTCAAAGGACCCTACAGGATGGGGACAGGAACAAGGATGGGAGTCGGGGAGGGGCTGTCAGGCAGAGGGCAGATGCAGCTCCTCGGGTGCCGCTGGCTGGAGTCCTTTGTCTCCATTTGCTCAGTGCGTAATTGTCATTTTGTGGGGGACTTCCTTGGTGGGGCTTTTCCATGCTTTTCCTCTCCCTGATGGTTACAAAGAGGAGACAGTCAGGATCTGGGAGGAGCTGGAGCCTTCCCCCTGTGCTGTTGAACTCTGGGAGGGGCAGCCAGAGGGGCTGAGAGTGCACCATCCTGAAAAGAGAGGGTCTTTAAGAGATAAGATTTAGGCTAGGGAAATTCACTAGAAAGAGACAGGTGGCCCTGGGTTTTTTTTCCTGCCATCCAAAGGGAACCAGTCTTACCCAAAGGCTTAAGGGGTCACCTTAGCCCAGTCTCAGGACACTCTTCTCCAATCAGATCGCTGCTTCTAGTTGCACTGCTCCTGGATTCTGTTCTTGGGGAACAGAAGGTGGCAGGACAGGCCCCACAATCTGCAATTCCAGCTCCCTCCAGAGGAGACAGTCCCAGCGTTTGCAAGAGAGCAGCTTGTGGCCTCCCTTAGGCAAGTTTAAAAGCCAGATGTCCTTTTTCCCAGAATGCGGAGTGGTGTGTACTATTCATCAGCTTGGGCTGCCACAGCACCATGCCAGACTGGATGGCTTAAACATCAGGAATTTATTTTCTGCCAGTTCTGGAGGCTGGAAAGTCCAGATCAAGGTGTTAAGACTTGGTTTCTGGTGAGGCCTCTCTCCTTGGCTTGCAGGTGGCACCTTCTCACTATGTCCTCACATGGCCTTTTCTCTGTGGAGAGGGACAGAGAGCATGAGCAGGCTCTGGTGTCTCCTCCTCTTCTTATAAAGACACTAATATCACCATATTAGGGCTTAAACCTATGACCTCATTTAACCTTAACCCCTTAAAGGTCCCATCTCCAAAAACAGTCACATAGCAGGCTACTGCTTCAACATATGCATTTGGGGGAGGGGACACCATTCAGTTCTTAACAGGGTGGTCACCGCAAACATGGAAAGTCAGAGCCTTCTCCCCTTCAGAATTCCCGCCCCCACCCAGGGATGGGGAGGAGGAGCAGAGAGGTATGGGAAGCAGACACGGAGAGTGGCAGGTACCATGCTGGGGTGGCTCAGGAGTGCTTCGGAGGACATATGGAACTGGCAGGGCTCAGTGCAGGGAGGCGGAGGCCCTGGGAGAGCCGTGTCCTGAGAAGGGCCTGGGCTACAACCCTGGGCAAGTTACTTCACCTCTGAGCCTCCGATGCTCTGTGAAATGGAAGGAATGTGCTTGCCTGTCAGGTGCAGGGAGAATTCAGTGAGATTGTGTGCCTAGCACAGTGCCTGACTCCCAGTAGGTGCTCAGCAAATGCTCCCATCCATCTGGGAGTATAGACTTAGGGTTTATCTATTTTTTTTTTTTTTTGGCTCTCTGGACTTTAAAACTCAGCATCTTCTGAACCAGAGGCATTTCTGATTAGCCCTTCCCTACCTATTTTCCTAGTATCACTCTTTAATCAGCTTGGGGAGGTGGCAGCATTTCATGGCCTCCGTAGTAACTCACAATGCTTCCTGGGGTATTTAAATTCTACTCTCTCATCAGCACTGAGCACCTACTTTGGGCCCTTTCCCGTGCTAGCCATTTGGGGGAAATATAGGTGAAGAGTGGCTGGGGTTTGAACCTTTAGGATTTCACAGCCATGCTGGATGGGATAAAACCAGCTCACATGGAGAATCAGAGAATGGGACAGTGCCACAAAACAGTCTACTGAGGCACAAGTTCTGAGTGCCTGGGAAGTGGTAGAGAGACCCCAGAGAGGGCTGCTGCAGTCTGGAACAGCTTCCTAGCAAGCTGTACCAAACAGGGCCTTGAAGGATGAGAAAGATCTGGCTGAGATGATACCCGACCCTCTAGGGAAATTCTTAAAGTAACTTCTAGGAAATGTCATTGCTCCTTAAAAAAAAAAAAAAAAAAAAAAAAGCAGGTTCTAATTCAAATTCCGCTGCACTACTGAAGTAGTGCAGGACTTATCAGAACCTTTAAAATGCTAATGGCAATTTCAAATACTCAGGGACAGGGCATAGGATGAAGTGTTCCTTGACTTTTATGGCCGTAGAATCTTTTTCTCATGGAACATCGTTTAGAACTGTGGGAGATGCTAGGCTGGGGTTTCTATGGGAAAAGTACAGCAGTGATAGAAGATGGCATAATTAGGGTACACTTAGGTGCTTTGTAGCATTGGCTGAAAAGGAAGCAGACCGGGTGGGCGTGGGGGAGTCTCAACTTGGTTCCAGGAGCCAGGCCAGCTTGATGCGTTTTTTTTTTTTCTAATGGTGGGAGGGCAGGCCAATAGTTGGAGAAACTAGAGGCCTGACAGTCGGTGATGGAAGAGATGTCTACTAAGCACGGTTGTCAGATCTTTTGCGGAGAGATGCGGGTGTGCGTGTGTCTGTCAGAGTGTAACAGGATCCAGCCCTCTGGGAAGGGGCTGACCAGAACCAGGCAGGGGGTTTCTGTCTAGGACAAGTAGGGTCCATTTTCAGGGGAGCTGAAATATTTGCAGGGGGTGCTCTGAGACCCACAGCCAATAAATAGGGAAGCAACATGCTTTTGGGCAGGGTCCATGTGGTTAGGGTTGATTTTGATGGGGCTGGGGGGCTTAGAGTTAGACCCCCTGCCCTGGTCAGGCCCCACTCCCTGGCTGGTGGGGGCGGGAGGCCTCTGAAGCTGCAGCTGGAGGGGCCGGGGCAGTGTTGCATGGTGTGATTAACCTACTAACCCAGGGCTCAGCCGGGACGCTGTGGCGTGTGACGAGGTGCCTGGCCTTCTGCCAACCAACTAACCCACTAACCAGGCCCGAGCATGCCCTACTAACCACCCCCCCGCAGCCAGATCCTACTAACTGTGCAGCTCATGGGCCTTTCAAGGGGCTGGGATATGGGGGCAGCCAAGGCTCCAGAAGGCTCTGCCTATGGGCTGGGATCTTTGTGCAGACCCACGTTCCAGGACAGAGAATGCAAATAAGACTCACCAACTCTGCCACTTCCTGTTGAGTGAGTTTGAGTAAGTCACCTCACTTCTCTCAACCTCAGTTTCCTCAGTGGTAGAATGCGAGTTCTGATACCTTACAGGTTGCAGTGAGGATTCCCGTCAATATAAGGGTCTCAGCACATGGCAGACACCTAAAAAAAAAAAAAGTATGAGGATGGAGGAAGGCCCCTCAAACCTGGTTGAACACGTCTGCTGCCTAGGCCCTGGCCTCTCTGGGTGTTCTGCACACAGATCCTTCTGCCTGGGGCAAGACACTTGGCTTTGAATCCATGTCACTTCCCCACATTCTTCCTCCGTCTCAGCTTTCTTTTCTGTAGGCAGCTCTTTTGTTCGATTACTAACCCGTCTAACCCCTGGGGTGCCTCAACTGCACCCCGATCATCCCTTAACAAACTAACGGACCTGCGTGCGTTCTTCCTTTTCTCTTAGCGACTCCTGTGTGTGTCTGCTGAGGTGCCCTGTCCGCTGGTGCTGTGCTCTGACTTACTAACCCAGCCCCTACTAACCCTGTTTTCTCTTCTTACTAACCCCAGCCCTGCCGAGCTCTGGGCTCCCCCCGGGGGCTGGTCCCCCTCCTTTTGGCAAGCAGATGACCTGGGGCTACTGGCCCTGTAGACAGATGTCCCACTTTGCTGCCCCATATTGGCTGTAAGATCAGAGTCCACTGGGCCAGGTCTAAGGCAGGGGATGGCCCTATTAACAAGACTCAGAGGAGGAAGAGGTGGTCCTGTGGATGTGGGAGGCTGGACTCTGAGTATGACATCTCTCCTATGTGCAGAAGTCTGGTTGCCACTGGGAGTAGGTGGGACCAGGGAAATCTCTGGGACGTGAGTGTGGAGGCCTGTTGGTCTAGACTCTAGACTGTGGAGCTCTGAGCTTTTGTGTCCTCTGGAAGGAAGCTGGGGAAGAATCCTCTCCATTGTTAAGTGACGGGGATAGAAGCTGTCCTGCACAGGAAGTCACGAGGGGGGCGTATCCCACGAGGAAGGCAGGAGGGGGCGTGCCCCTCACCGGAAATTAGCAGAGGGGCGTGTCCCACACCGGAAGTCAGAAAGCGGAGCCTTTCTTACACCGGAAGTCAATGAAGCGGGTCTTTCCTACGCTAAAAACCACTGAGTGGAGTATTTAGTACACAGGAAGTCGGCCAGAGAAACATTTCTCATATTTGAAGGCCGGAAAGAGGGACATTTCTGACACCGGAAGTCAGTGAGAGGACTCTTTCCCACACAGGAAGTCAGCTAGAGAGCCGTCTCCCCTCTCTGGAGCCGAGAGAGGCCGGTTTCCCCCACCGTAAGTAGACGTGGGGCCGTGACCGGAAGTCCTTGGGAAAGATCCGTCCCATTCCCGGAAGCTAGAGGGCGTTAGTTGTCGGGTTGAAAAGGGGTGTGGGGAGGGGAAGCAGCTTTACCCCGGGCTCGGAGTTTGCAGGAGAGAGAAGTGGGGAGCAAGAAGTGAACCTCAGGGGCTCACAGGGTTCCCGCAGATGCTCAGGCCGGCCAGGAATGCATCTCTGGCTCTCTGTTCCCACGGACGTCACTGCCTCAGCCAGCCTCCCCCAGAGCCCGCCAGCCGCTAAGCCGGGGCCACACCTGGGGGTGATTTCATGCCTCACCTCCAGTAGGCACCTTGGTTTCTTTGGGCTAATCTCTGGCTCCCTTGCGCTAACTCTTGCTCTCACCCAGCTAATCCCTGCCTCACCCTGACTGCCCCAGGGGCTGACCACTAACAACCAACCTGGCCCTGTCTGGGGGTTCCAGGCTCCTGGCCTGGCCCTGACCGGTTCTTAATTAACCTTTCCTTCACCTTGACTAACTCCTGCCTTCCTGGTCTGTTCCTTTCAGCAGAAACTAATGGTTTGTGGATTTTTTTCTGACTAACAACAGGTCTAACATTCCTCGTTACTGTTAACAGCTTGGATGTCGGCATGGCTGGGAAGGGGCTAACACAGCTTTGAACTTGGCTAACACAGGTTTGAACTTGGCTAACACAGGTTTGAACTTGACTAACACAGGGAAAAGCATAGCTAACAATTTTGGGCGTGGTGGCTGCTCTGAGTCAGAACAATCAGAAGTCGGTAAAGATGGTAGTTTTCTAAAGGAGGTGCCAGGGCTCTGGTGTGGACCAGGCCTGATGGAGCAGTGGTACCCACCAAGGTGGGGTCAGAAGTATAGCCAGTCTTGCAAGGTTTTGGCCATTGGGCATATCTTCACTCCTCATAGTCTGCATTTGGTTTCAGTTCTTAAAAAAATATAGCCTTATAGCTACAGTAGTTTGCACAAGTAGATGCAGCTCTTATAAACCTTAAAATACCTGTCTGGTGTCTACAGAGCATATGCCATTTTGTATAGAGTCACCCTTCCCCAGGCCAGGGCCTAGAGTCTTCATTTTGGGGACTTTGTGTTTTGGAAGTTCTAGGACATAAAGCTTTAGATCAGAGTATTCAGAAGGGTTATAACTCCGTCAGTCATTTACATGTTAGTAGTATAAATTATCTGAGCTTCCTGTTCTAACTTTTAGCTCTTCTAGCATAAACTCTTCTGTGCAATTTAGCTGCACCGAGGAAACGGGAGTTTTTCTGGAAGGGACTTTTGATCTCTTTAGACTGAGGGAACGTCCTTTGGGAGTAGAGGGGCAGGGAGCATACGCAAGGGATTCCAGGTGCAGGTAAAAGGTGGCACTAGTTCAAGGTTTTGCTGACTCAGTCTGGTAGTCAGAGTCTGCAGGAGAAGACAGTTCAAGGCAGGGCCTGGAGGATTGGATCAGTTTAGGGACAGGTCAAAGGCTGGCTTACAGACCTTAGAGGCAGGTTGCTTGGGTCGTTGAATGCTAGTCTGGTGCTGAGAGCCCTTTTCTCTGGCAACTGTGGACTCAGAGCTAACCAATTGTAGTTGGCAGTGGGGGTGAAGGGTGATCCAGAGGCCTGAGCTGCAGAGGGCACAAGAGAGAAAAGATGTCTTAGAAAGAGCTTTGAGAACATGCCTTGGCTGCTGGCAGGGACCTTGGATGGGGTAGTCTACACCCGGAAGTGCCTGCCTGCCATCCTCTAGTGGCTGCCTTGCTCCATTTCACTCAAAGCAGGAAGCTCACACCTCCTATTCCTGAAACTCCTCTTTGTTTAACTGCAAAGACTTGATGCTGCTAAGGATCTACTATGTGCCAGGCACTGCTCTGGGCGCTGGGACCTGCACCTGGGCTTTTTCGTCATGGTGCTTTTATAGCCTAGTGGGAGAGTTGGTGAAGTAGATAGTGATTCAGTGAGATGGGTGTTATGATTGGTCAGGGGTCTGTGGGAGCACCAAGGAGACAGACAAGATTGATGTGCACCTACTCTGTGCCAGGCGTGTGCCAGGCATTGGGGATGTAGTGGTAGTTAAACACCATTTGGTCTTCAGGAGCTTTAATTCTAGTGTGTTGGGTGCAGGGGGGTGGAATGGGGACAGAGAGACACCTAATCCACCCTGTGGTGGCTTTCTGGAGAGGGAGGCATCTAAGCTGAGCTGTGGCTGGGTGGAGTGTGGGTGGGGATGAGTTCCGGGCAGCGAGAGTGGTGGACACCAGTTTCTGGGGATCAGAGAGGATCCAAAGAGGTTCTGGAAGGTTCATGTGGAATGTAGCAAGAGATAGGAGACATGGACATGGTGCCGGGTCTGGTTGCCAAGAAGTTTAGATTTTATCCTTAGGCCTTGGGGAGCGACGGATATGATCTGAGAAAGGGAGTTAGTGGATTTGAGTTTTAGGCTGGCCATTTGGCTTTTCCAGCCCAGGTGGAACTCAGAGGAGTTTGCAATGGCCTCTGGCCACATTTTAGACAACTGAGCAGAACTTTTTGAAACTAGGAAGACCCTTTGGTCCATCTTTTGATAAACAGAATCCATACATGTCTACCCCAGTTGGAAGTATCTCTGCAATGACTGGAAAGTAAAGAGGACCAAGGTGAAAATAAAGGCTCGGAAGGGGAGCAATCTTGAAAACATGTCATCCCATGGTGGTGGGAAGTCCCTGGAGAAGATCAGGGGAAACACAGTCATAGGCTGCAAGTCTATAAGATAATTCCATTGGGGAGGGAGCCCATTTGTCATGCATGGCTGCAAGGGGCAGATACAAGTGTGGAGTAAGCTTGCAAGAGCTGATCCTGGTCCCAGAGAGGGAAAAATATGCCTTGGTGGGTAATGAACCTTTTGTTCCCAGAGGCAGAAGGATTGGGACTAGGCCAACATAGAGATTGGCGATGGTTGTGAGATTCTAAGAGTGTGTGTGCATCTTGACAATATTAGAGGAGGCTGAGCCCAAGCAGGCACATTCTCTTCGACCCCTCCCTCATTCAGTCTGCTTTGGAGTCTACTGAACATCAAGCTTGCTATGAGCAGGATCTTAGAGCTGAGGAATTGGCCTCCCAATCCGAACAGGTGTTATAATCCTTTCTTAATAGGTTGTGCTGTGGACCCAATGTGAGGGCTGTGCTGGTGTAAATGGTGACATGTTGAGCTGGGGGGATGCTTTCGGGGTGGGGGGACTGGTTCCATTCCATCAAAGGCCCTCTTGAGAGTCTATCCAGGGACCCATTGTTTTACTTTAACAGACCAGAAAAGATGTTTGTTTTCCATGTCATTACCCCCAGGGGATACCGAATGTGTGGGTAGAAATTTCTCTGTAGATTAAAAATCAGATTTTTACATGGATTCAACAAAGGAGCGTCACTTGGATTTTTGTTTTCATCCATGAATGTAGCTGCTTCTGTGTAAAATGCCATTTTGCTATTAAAAATCAATTCACGCTGGAAAAAAAAAAAAA)
<400> 1
<210> 2
<211> 22
<212> DNA
<213> Artificial sequence
<223> miRNA-17-3p gene (5'-ACUGCAGUGAAGGCACUUGUAG-3')
<400> 2
<210> 3
<211> 5958
<212> DNA
<213> Artificial sequence
<223> GALNT10 Gene (GAGTTGGAGCGGGGCCGGCGCCGCAGCCGCTTCTGCTGGCTGAGCTGCTGCCGCCGCCGGGCGGACGGGCGGACGCGCGGAGCTGGGGGCGGCGCGGCGGGGCCGGCGGGGCGCGGCGGGGCTGACCGGCCCCGATGAGGCGGAAGGAGAAGCGGCTCCTGCAGGCGGTGGCGCTGGTGCTGGCGGCCCTGGTCCTCCTGCCCAACGTGGGGCTTTGGGCGCTGTACCGCGAGCGGCAGCCCGACGGCACCCCTGGGGGATCGGGGGCGGCGGTGGCGCCGGCGGCGGGACAGGGCTCACACAGTCGACAAAAGAAAACGTTTTTCTTGGGAGATGGGCAGAAGCTGAAGGACTGGCATGACAAGGAGGCCATCCGGAGGGACGCTCAGCGCGTAGGAAATGGAGAACAAGGAAGACCTTACCCCATGACCGATGCTGAGAGAGTGGATCAGGCATACCGAGAAAATGGATTTAACATCTACGTCAGTGATAAAATCTCCTTGAATCGCTCTCTCCCAGATATCCGGCACCCAAACTGCAACAGCAAGCGCTACCTGGAGACACTTCCCAACACAAGCATCATCATCCCCTTCCACAACGAGGGCTGGTCCTCCCTCCTCCGCACCGTCCACAGTGTGCTCAATCGCTCGCCTCCAGAGCTGGTCGCCGAGATTGTACTGGTCGACGACTTCAGTGATCGAGAGCACCTGAAGAAGCCTCTTGAAGACTACATGGCCCTTTTCCCCAGTGTGAGGATTCTTCGAACCAAGAAACGGGAAGGGCTGATAAGGACCCGAATGCTGGGGGCCTCAGTGGCAACTGGGGATGTCATCACATTCTTGGATTCACACTGTGAAGCCAATGTCAACTGGCTTCCCCCCTTGCTTGACCGCATTGCTCGGAACCGCAAGACCATTGTGTGCCCGATGATTGATGTAATTGACCATGACGACTTTCGGTACGAGACACAGGCAGGGGATGCCATGCGGGGAGCCTTTGACTGGGAGATGTACTACAAGCGGATCCCGATCCCTCCAGAACTGCAGAAAGCTGACCCCAGCGACCCATTTGAGTCTCCCGTGATGGCCGGTGGACTGTTCGCCGTGGATCGGAAGTGGTTCTGGGAACTCGGCGGGTATGACCCAGGCTTGGAGATCTGGGGAGGGGAGCAGTATGAAATCTCCTTCAAGGTGTGGATGTGTGGGGGCCGCATGGAGGACATCCCCTGCTCCAGGGTGGGCCATATCTACAGGAAGTATGTGCCCTACAAGGTCCCGGCCGGAGTCAGCCTGGCCCGGAACCTTAAGCGGGTGGCCGAAGTGTGGATGGATGAGTACGCAGAGTACATTTACCAGCGCCGGCCTGAATACCGCCACCTCTCCGCTGGGGATGTCGCAGTCCAGAAAAAGCTCCGCAGCTCCCTTAACTGCAAGAGTTTCAAGTGGTTTATGACGAAGATAGCCTGGGACCTGCCCAAATTCTACCCACCCGTGGAGCCCCCGGCTGCAGCTTGGGGGGAGATCCGAAATGTGGGCACAGGGCTGTGTGCAGACACAAAGCACGGGGCCTTGGGCTCCCCACTAAGGCTAGAGGGCTGCGTCCGAGGCCGTGGGGAGGCTGCCTGGAACAACATGCAGGTATTCACCTTCACCTGGAGAGAGGACATCCGGCCTGGAGACCCCCAGCACACCAAGAAGTTCTGCTTTGATGCCATTTCCCACACCAGCCCTGTCACGCTGTACGACTGCCACAGCATGAAGGGCAACCAGCTGTGGAAATACCGCAAAGACAAGACCCTGTACCACCCTGTCAGTGGCAGCTGCATGGACTGCAGTGAAAGTGACCATAGGATCTTCATGAACACCTGCAACCCATCCTCTCTCACCCAGCAGTGGCTGTTTGAACACACCAACTCAACAGTCTTGGAAAAATTCAATAGGAACTGAGCCCTCATGTCCCCTTGGCAGGCCCCCCAGGGTCTGGCACTCACTGCAGACTTCCTCTTTCAAGGGAGGCAGGGCCCCTGTGGGCACTAGGTGTAAAAGGTGCTGGCCAAATGGTTCAGGGTGAAGAGGGCTCTTGATTCAGGGGCTGGGGTCTGCCTGGTCCTTGAGCCCCTGAGTTGTGGGGGTAGGGTGAAGAGCATATCCCACAAGAGGCCCCACAGGGAGCAGAGACTGCTTTAATCCCTGCTGACATCACGGAAAAGCAACAGAGCCTTTTCAACTTTGTCACTATGTCCCCTTGAACATTATGTGGGAGAACACCAAGGTAGCCTAGGCCACCCAAAAGTGAGTCCTGCGAGGTTGCCCAGCCCTCAGATGGCTCTCCTACATGATGGTGCTTTAGAAACAAAGGTAAAATTTGCCTGTTTGGGGCAGCTTTTAGTATCGATGCCACTCATCTGCAGCAGAAGAGAAAGAAGTCCTCTTGGGGCTTTTTAGTTTCTGCCGTCCTGGGGGGAACATTGCAGTTACTGCACAGCTTCTGTTCTCTGTCACAACCCCAGGTGATTTGGTCCGGTCAAAGGCCATACTTGGGGCCCTAAGAGTGTTCAGTATTGAATGCTGATCAGCTGCCAGGTGAGGAGTCAGAAGAGGGAGCCCCCCTAGACATTTCTTTGCAGCTATGGACATGCGGGATATCTCCCCCTGCTCTCTGGGTATTTGAAATGTCAATTTTAGCACTCTCCAGGCACAAGGACAGCCCAGCACCAGCTTTACAGGGCAGTGTTTCAGATGGCCCTGAGCCCACGGAAAAGGCCAGGTAGACCTCCAAACTAGAAATGCTGGCTGATTTGCCCTGATCCATGCTTCCATTTCCCTGTCTCTCTTCCCCAGGCAATTACTGGCCTCAAAAGAGGAACAGAGGTGCTGCGAGGTGCTCACCTCACAGAGTCTGGAGGCCTCCAGGATCAACTGTGGGCAAAGTGCCTGCCTCTGACCTCATCATGGTTCTAGTTCTCATACAGAACTCCAGAATTTTTAAAGAACTCTATAATTGGATTGCAAACTAGGATGCTACATAGGATTCTGGTATTCCACATCCAATATGGATTTCTAGAATGCTGTGATTAAAGGAGCCAGCCAGGTGTAATACAGTCAAGGCAGCCCCCAGCCTAGAGACAATCTGTGAAATCCAAAGTTGGTGGTGTTGGGAAAGCAGGGGGACATGTGTCCCTCAGCTCAGCAGAGGCTGTGGTACAACATGGTCCTTGGTGAAGACCTGCACCCCTGGAACCTCCCACCATCATCACAACTGTAGTCTCATTTGCAGTGGAGAAAAGAACCCGACGTCCCACAGCCAGATATACACCCAGCTCCATGCCAGCCCTTCATGTTTACCTTTTGCTTTGTTAATTACATGTCAGACTCCTAGAGGGCCTCCAGACTAATAGGAAGCATTTCTGTAACCAACCTGCCACCCACTGATTCAGAAATGGAAATCACATTCCACAATCTATGGCTTCCACCAGCTAGCCCAGGAAATACTTGAAATCAGCATTCCAATTAGTGTTGAGTCTCTTGATTGTGTCATTTACCAATTAAATAACTGAGACCTAAGTCTGGGAACAGAGCCACGAATCTGCCTTTGAGATGCTGGCAGATCTCAAGGCCATCAATTATTGGGGGAGGGAGGGACAAACACTCCCAATCATCCACCAGTCAGACTGAATGTGTAGCTGGCGAGGAATTACTTCCACTTCTGGCCCAGCACAAGCCCTGCTTTGGCCACCTGTCTGCAAGAGAGGCGGCCCCTGTGCTTGCAACGCTTACGTGTTGATCCCAGTGTCCTTTTCCAAATGAGTGCTGTAGCTTTAGAAGTGGCCCTCTATAGAAAGAAGTCAAAAGATGAGGCCCCTTCTAGAATCTAGGATAACAAGAGTGTTGACAGTTTGAGGAGTCGAATTGAGATTCATCATCAAAGAGCAATGCAGCGTCGTTAAAATAAAAACTGTGCCTTTTAAAAAGAAAAATGCAAATATAGAGCAAATCCCTAAACTTGAACCATTTCCTAGTGCCTTGCTAGACAAACATAAAGGGGCAGGGTTGTGGGGAGGGGAACGTTTTTGGTGGTGTGTGCAGTTCCTACTGGATGAGTGTGTGTTTCTTAATGTCTCATTTCAAGCAGGAGATGTTGGGTCTGGAGCAAGATCTGAGACTGAGATGTCCCCCAAGGGTGACAGGTCAGATTTATTTCAGTCAGTGCAAGTCACACTCCAAACTAAAGGCTGGGCAGTGCGTTTAGTCTGTGGCCTAGAAGACCTCATCAGCCCCCGAGAGGAGGCCTTGCATTACCTCACTGGGACCTGTTTGGGGGCCATCCCTGCGGTCCACCCTCTGAACCCCCAGCATGTTTGTCCTGTTTCTCACCATTGGGTTAAGGGGTGCCGAGCACTAGCTAGACTTCCACATAGTCCCACCCCAAGTGGGCGGCAGTGTTCCTGGCATGACCAGGATTCCTGTGAAAGCAGGAGCAGCAGCAAGCCGTCCCGGGCCTGCCTTTCCCATCCTTTGGTTCTCCTTTCCAGTCTGGGTTCACACCCTGAAAAGGGATGGGTGTGTCCTCTGAGCACTCTGGCATTTGTCATTGCTGAGCCCATATCAGTAGGTCCTGGGACTTGACAAAGTATGTGGGAGGGGAAGGAAGGACAGAACTTGACTGGCTCCATTTCATGGACCAACTGATC)
AATTGCCAGTACTAAGCCACTCATTGTTATGGCTTCCTTTTTGAAAACCACCTGTCTCAAGGATTCAGGTTTCTGCTCACATCCCCAGCTGATGCTCAATAAAACTCAGCCAGGAGCATATGGAGATGCTGACAGCCAGGTAATGGGTGAGACTGTGGGGTCCCTTTTCCTCTAAAGCCTTTACTCTGAGGATAAGGTCACAAAGTAGGGTGTGACTTGAAAGTATCGTGACCATGTGGCCCACCAGCAGCCTTTCCAAAGGGGAACTCCAGAGACATTTCATAATGCAAACAGCACTGTTGCTTTAAGAACAAGGCCTTTGGAGGTGGCTAAACTTGCACGCACGTGTGTGAAAAGCCATCCCATCTTCTGCCTCCAGTTGGAGCTTTCAGCTGTTAAAACAGTCAGAAACTATTGATTCTTCCCTTTAGGAAAAAATGCTCAGGCAGAACGGGGTACATCCACAGGAGGAATCGGACGAGAGGATGTGACATTCGGTCCAGGAGAGAAAGAGCAGTTTCTGTTAAAGATGTAACAAATGGATTTCCAAAGTCTACATGACATTCACTTTTCAAACTTCCCACCAGTTGAATTTCTTTTTTTCCTTAAGAAACAGGTGATGTCTTGGAAAACAGCTCCTTATGTCTCTCTGTGCATCTCCATTTTCCTAGTCTCTGGAGTCTCAAAAAGAGTGGCAAAGCACTTTACAGTAGTAACTGAGGAATCAGAGTCTCTGCTTCAGCGATATCTAGTTTGTACAGTTGGGTGATCTTTTGTAATTCCTAGGAGGTAATGCATTTTTAATGTTTTCTGAAGCTTTGTAAGTGTGAGAGAGGGACAAGAAGTGCAGTTCTGTTCTGGAATTCCTTATTGCTTTCAACGGACACTCTTTGTGAAAAATCCAAGTAATATTTTAGTTCAAACTTGATCTTGAGCCAAGGCCCACTGCCACCTCTGGGATGGGAGTCGGACCTACATACCAAGTGACAAGTTCACCTTAACATCTGCTTCCAGAATGGCTTTGATTCAGCCGTGCCAGGCAACAGAACAGGGTCAGACTCCTGCTCTGTTATTGGCTTGAAGACTAGGATCCCAAAGGGGTTGGAGGCAGGGAATATTTGAAAATTCAGACTGGAATTCCAGGCCAAAAGCTCAAGACCACCAGCCTCTCCTCCTGCCTGGAAAAATAAGCCTTTGTGAAAGACTGATTTACCATGTACAATTGTGATTGTGAACGTTGTTGAGTAAACCTCCAGACTTTCTCTAAA）
<400> 3
<210> 4
<211> 18
<212> DNA
<213> Artificial sequence
<223> specific upstream primer for MIAT gene fluorescent quantitative PCR (5'-CAAGGTCCACAGAACGAG-3')
<400> 4
<210> 5
<211> 17
<212> DNA
<213> Artificial sequence
<223> MIAT Gene fluorescent quantitative PCR specific downstream primer (5'-TAGCCCTAACGCCAAAT-3')
<400> 5
<210> 6
<211> 22
<212> DNA
<213> Artificial sequence
<223> GALNT10 Gene fluorescent quantitative PCR specific upstream primer (5'-AAAGTTGGTGGTGTTGGGAAAG-3')
<400> 6
<210> 7
<211> 19
<212> DNA
<213> Artificial sequence
<223> GALNT10 gene fluorescent quantitative PCR specific downstream primer (5'-AGTGGGTGGCAGGTTGGTT-3')
<400> 7

Claims (6)

1. A ceRNA regulation network for early diagnosis or detection of cerebral aneurysm is characterized in that the ceRNA regulation network is a IncRNA MIAT-miRNA-17-3p-GALNT10 regulation network, wherein the nucleotide sequence of IncRNA MIAT is shown as SEQ ID No.1, the nucleotide sequence of miRNA-17-3p is shown as SEQ ID No.2, and the nucleotide sequence of GALNT10 is shown as SEQ ID No. 3.
2. The use of the cerRNA regulatory network for early diagnosis or detection of cerebral aneurysm, as claimed in claim 1, in the preparation of a medicament for early diagnosis or detection of cerebral aneurysm.
3. Use according to claim 2, characterized in that: the drug promotes the expression of lncRNA MIAT genes and/or promotes the expression of GALNT10 genes and/or inhibits the expression of miRNA-17-3p genes in early diagnosis or detection of cerebral aneurysm.
4. The use of the cerRNA regulatory network for early diagnosis or detection of cerebral aneurysm as claimed in claim 1 in the preparation of a kit for early diagnosis or detection of cerebral aneurysm.
5. Use according to claim 4, characterized in that: the kit comprises
MIAT gene fluorescent quantitative PCR specific upstream primer: 5'-CAAGGTCCACAGAACGAG-3' the flow of the air in the air conditioner,
MIAT gene fluorescent quantitative PCR specific downstream primer: 5'-TAGCCCTAACGCCAAAT-3', respectively;
GALNT10 gene fluorescent quantitative PCR specific upstream primer: 5'-AAAGTTGGTGGTGTTGGGAAAG-3' the flow of the air in the air conditioner,
GALNT10 gene fluorescent quantitative PCR specific downstream primers: 5'-AGTGGGTGGCAGGTTGGTT-3' are provided.
6. Use according to claim 5, characterized in that: the miRNA-17-3p gene expression level is in negative correlation with the cerebral aneurysm disease, and the MIAT gene and the GALNT10 gene expression level are in positive correlation with the cerebral aneurysm disease risk.
CN202210407039.XA 2022-04-19 2022-04-19 CERNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof Active CN114717318B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210407039.XA CN114717318B (en) 2022-04-19 2022-04-19 CERNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210407039.XA CN114717318B (en) 2022-04-19 2022-04-19 CERNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof

Publications (2)

Publication Number Publication Date
CN114717318A true CN114717318A (en) 2022-07-08
CN114717318B CN114717318B (en) 2024-04-02

Family

ID=82243645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210407039.XA Active CN114717318B (en) 2022-04-19 2022-04-19 CERNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof

Country Status (1)

Country Link
CN (1) CN114717318B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107557467A (en) * 2017-08-10 2018-01-09 李永东 A kind of clinical marker thing related to cerebral aneurysm and its application
CN109777877A (en) * 2019-03-19 2019-05-21 宁波市第一医院 Detection kit for auxiliary diagnosis of cerebral aneurysm based on PTBP1 methylation and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107557467A (en) * 2017-08-10 2018-01-09 李永东 A kind of clinical marker thing related to cerebral aneurysm and its application
CN109777877A (en) * 2019-03-19 2019-05-21 宁波市第一医院 Detection kit for auxiliary diagnosis of cerebral aneurysm based on PTBP1 methylation and application thereof

Also Published As

Publication number Publication date
CN114717318B (en) 2024-04-02

Similar Documents

Publication Publication Date Title
Long et al. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers
US20240018598A1 (en) COMPOSITIONS AND METHODS OF USING TRANSFER RNAS (tRNAS)
WO2017055487A2 (en) A METHOD FOR DIAGNOSING A DISEASE BY DETECTION OF circRNA IN BODILY FLUIDS
JP2014508525A (en) Method for identifying a subset of polynucleotides for in vitro determination of the severity of a patient&#39;s host response from an initial set of polynucleotides corresponding to the human genome
EP2646554B1 (en) Prediction of spontaneous preterm birth by measuring cell free nucleic acids in maternal blood
US20230036585A1 (en) Novel methods for early identification of bone healing ability in injured patients
EP2759602A1 (en) Non-invasive prenatal genetic diagnostic methods
US20210404002A1 (en) Quantitative Algorithm for Endometriosis
US20130157272A1 (en) Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
May et al. MicroRNA signatures of perioperative myocardial injury after elective noncardiac surgery: a prospective observational mechanistic cohort study
AU2012308365A1 (en) Methods of detecting sepsis
Ge et al. Differential expression of circulating miRNAs in maternal plasma in pregnancies with fetal macrosomia
US11149315B2 (en) Method for predicting cervical shortening and preterm birth
US10954564B2 (en) Combinations of cell free nucleic acids
CN114717318B (en) CERNA regulation network for early diagnosis or detection of cerebral aneurysm and application thereof
WO2022057193A1 (en) Long-chain non-coding rna and use of inhibitor thereof
CN112522391A (en) Application of hsa _ circ _0008961 as gout diagnosis marker
EP3198013B1 (en) Microrna biomarkers for posttraumatic stress disorder and methods of use thereof
US20210095347A1 (en) Combinations of cell free nucleic acids
CN112795640B (en) Application of three microRNAs as RA markers and kit thereof
EP4183888A1 (en) Mirna signature for identification of the receptive endometrium
CN114480656B (en) Application of SLC12A3 and/or SLC12A9 as grape membrane melanoma treatment and prognosis detection index
LU102676B1 (en) A Biomarker for Severe Asthma and Application Thereof
CN117904272A (en) MiRNA regulation network for early diagnosis or detection of smoke diseases and application thereof
JP2023536420A (en) Biomarkers for cognitive status

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant